Sign Out
Rosuvastatin is contraindicated during pregnancy or lactation as the safety of rosuvastatin during pregnancy and whilst breast-feeding has not been established. Women of child bearing potential should use appropriate contraceptive measures.
Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. If a patient becomes pregnant during the use of this product, treatment should be discontinued immediately.
Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in human (see CONTRAINDICATIONS).
